Joint medicine-information and pharmacovigilance services could improve detection and communication about drug-safety problems

Drug, Healthcare and Patient Safety

Volumn 6, Issue 1, 2014, Pages 89-92

  Schjøtt, Jan ^a,b   Bergman, Jenny ^a  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

Author keywords

Database; Drug safety; Pharmacovigilance; Pregabalin

Indexed keywords

PREGABALIN;

ARTICLE; DATA PROCESSING; DRUG DATABASE; DRUG INFORMATION; DRUG MISUSE; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; HEALTH CARE PERSONNEL; HUMAN; NORWAY; NORWEGIAN ADVERSE DRUG REACTION DATABASE; QUALITATIVE ANALYSIS; QUESTION ANSWER PAIR DATABASE; RELIS DATABASE; SYSTEMATIC REVIEW; WITHDRAWAL SYNDROME;

EID: 84903982762     PISSN: None     EISSN: 11791365     Source Type: Journal    
DOI: 10.2147/DHPS.S63680     Document Type: Article

References (15)

1. Uppsala Monitoring Centre. Safety Monitoring of Medicinal Products: Guidelines for Setting up and Running a Pharmacovigilance Centre. Uppsala: Uppsala Monitoring Centre; 2000.
2. Arimone Y, Bidault I, Dutertre JP, etal. Updating the French method for the causality assessment of adverse drug reactions. Therapie. 2013; 68(2): 69-76.
3. Oosterhuis I, van Hunsel FP, van Puijenbroek EP. Expectations for feedback in adverse drug reporting by healthcare professionals in the Netherlands. Drug Saf. 2012; 35(3): 221-232.
4. Schjøtt J, Pomp E, Gedde-Dahl A. Quality and impact of problem-oriented drug information: a method to change clinical practice among physicians? Eur J Clin Pharmacol. 2002; 57(12): 897-902.
5. Schjøtt JI, Reppe LA, Roland PD, Westergren T. A question-answer pair (QAP) database integrated with websites to answer complex questions submitted to the Regional Medicines Information and Pharmacovigilance Centres in Norway (RELIS): a descriptive study. BMJ Open. 2012; 2(2): e000642.
6. [No authors listed]. Gabapentin and pregabalin: abuse and addiction. Prescrire Int. 2012; 21(128): 152-154.
7. Grosshans M, Lemenager T, Vollmert C, etal. Pregabalin abuse among opiate addicted patients. Eur J Clin Pharmacol. 2013; 69(12): 2021-2025.
8. Schifano F, D'Offizi S, Piccione M, etal. Is there a recreational misuse potential for pregabalin? Analysis of anecdotal online reports in comparison with related gabapentin and clonazepam data. Psychother Psychosom. 2011; 80(2): 118-122.
9. Bodén R, Wettermark B, Brandt L, Kieler H. Factors associated with pregabalin dispensing at higher than the approved maximum dose. Eur J Clin Pharmacol. 2014; 70(2): 197-204.
10. Toth C. Drug safety evaluation of pregabalin. Expert Opin Drug Saf. 2012; 11(3): 487-502.
11. Härmark L, van Puijenbroek E, Straus S, van Grootheest K. Intensive monitoring of pregabalin: results from an observational, web-based, prospective cohort study in the Netherlands using patients as a source of information. Drug Saf. 2011; 34(3): 221-231.
12. Westin AA, Bramness JG, Chalabianloo F, Rygnestad T, Slørdal L. [Pregabalin should be moved to the prescription group B]. Tidsskr Nor Laegeforen. 2013; 133(6): 615-616. Norwegian.
13. Bergsholm P. [Prescription group C correct for pregabalin]. Tidsskr Nor Laegeforen. 2013; 133(10): 1044-1045. Norwegian.
14. Norwegian Pharmacovigilance Advisory Board. Minutes of meeting of December 11, 2013. Available from: www.legemiddelverket.no/Bivirkninger/bivirkningsnemnda/referater/Sider/default.aspx. Accessed April 30, 2014.
15. Karimi G, Star K, Norén GN, Hägg S. The impact of duration of treatment on reported time-to-onset in spontaneous reporting systems for pharmacovigilance. PLoS One. 2013; 8(7): e68938.